Mead Johnson & Company's latest lobbying report covers Q4 2025, at $80K. The four quarters Q4 2025–Q3 2026 total $80K. Its first report covers Q4 2022; the issues it reports most are Government Issues and Health Issues.

Mead Johnson & Company

Latest quarter: No record; Q3 2026 · 0 reports
Last 12 months: $80K; Last 4 quarters
vs last quarter: No record; Q3 2026 against the quarter before
First report: Q4 2022; The first quarter a report named it

Lobbying by quarter

Mead Johnson & Company lobbying by quarter
Quarter	Amount	Reports
Q4 2022	$60K	1
Q1 2023	$70K	1
Q2 2023	$30K	1
Q3 2023	$30K	1
Q4 2023	$30K	1
Q1 2024	$30K	1
Q2 2024	$180K	1
Q3 2024	$80K	1
Q4 2024	$180K	1
Q1 2025	$560K	1
Q2 2025	$80K	1
Q3 2025	$80K	1
Q4 2025	$80K	1
Q1 2026	$0	0
Q2 2026	$0	0
Q3 2026	$0	0

By issue

Health issues$225K · 3 reports
Government issues$190K · 4 reports
Trade$15K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

HOUSE OF REPRESENTATIVES6 reports
SENATE6 reports
White House Office1 reports

Firms it paid

Firm
In-houseMead Johnson & Company	$1.5M	13 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

	Filed by		Issues
01/14for Q4 2025	In-house	$80K
01/14for Q1 2025	In-house	$560K
25/10/03for Q3 2025	In-house	$80K
25/07/16for Q2 2025	In-house	$80K
25/04/21for Q1 2025	In-house	$70K
25/01/21for Q2 2024	In-house	$180K	Health issues
25/01/21for Q4 2024	In-house	$180K
24/10/21for Q3 2024	In-house	$80K
24/07/22for Q2 2024	In-house	$30K	Health issues
24/04/17for Q1 2024	In-house	$30K	Health issues
24/01/19for Q4 2023	In-house	$30K	Health issuesTrade
23/10/19for Q3 2023	In-house	$30K	Government issues
23/07/17for Q2 2023	In-house	$30K	Government issues
23/04/19for Q1 2023	In-house	$70K	Government issues
23/01/11for Q4 2022	In-house	$60K	Government issues